| 1 |
32771436 |
10.1016/j.drudis.2020.07.021 |
2022 |
Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy. |
MCL1 |
| 2 |
33514658 |
10.1158/1541-7786.MCR-20-0973 |
2022 |
Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells. |
MCL1 |
| 3 |
33853293 |
10.3324/haematol.2020.272609 |
2022 |
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. |
MCL1 |
| 4 |
33870156 |
10.1016/j.jhepr.2021.100250 |
2022 |
Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the <i>Mdr2</i> <sup><i>-/-</i></sup> mouse. |
MCL1 |
| 5 |
34153472 |
10.1016/j.bmcl.2021.128215 |
2022 |
Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold. |
MCL1 |
| 6 |
34343635 |
10.1016/j.canlet.2021.07.045 |
2022 |
Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance. |
MCL1 |
| 7 |
34601571 |
10.1182/blood.2021013156 |
2022 |
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. |
MCL1 |
| 8 |
34610112 |
10.1182/bloodadvances.2021004513 |
2022 |
Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation. |
MCL1 |
| 9 |
34625423 |
10.1158/0008-5472.CAN-21-1023 |
2022 |
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. |
MCL1 |
| 10 |
34728569 |
10.1158/1535-7163.MCT-21-0511 |
2022 |
Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas. |
MCL1 |
| 11 |
34913076 |
10.3892/ijo.2021.5292 |
2022 |
Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme. |
MCL1 |
| 12 |
35023102 |
10.1007/978-3-030-78787-5_20 |
2022 |
Early and Very Early GRIM19 and MCL1 Expression Are Correlated to Late Acquired Prednisolone Effects in a T-Cell Acute Leukemia Cell Line. |
MCL1 |
| 13 |
35035775 |
10.18632/oncotarget.28177 |
2022 |
GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells. |
MCL1 |
| 14 |
35058488 |
10.1038/s41598-022-04916-6 |
2022 |
Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma. |
MCL1 |
| 15 |
35136485 |
10.18632/oncotarget.28189 |
2022 |
GZ17-6.02 and axitinib interact to kill renal carcinoma cells. |
MCL1 |
| 16 |
35185150 |
10.1038/s41392-021-00870-3 |
2022 |
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. |
MCL1 |
| 17 |
35233562 |
10.15212/amm-2021-0002 |
2022 |
The regulation of neuronal autophagy and cell survival by MCL1 in Alzheimer's disease. |
MCL1 |
| 18 |
35704690 |
10.1182/blood.2021014304 |
2022 |
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. |
MCL1 |
| 19 |
35979721 |
10.3324/haematol.2022.280631 |
2022 |
Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes. |
MCL1 |
| 20 |
30055346 |
10.1016/j.tranon.2018.07.007 |
2021 |
Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. |
MCL1 |
| 21 |
31501195 |
10.1101/cshperspect.a035089 |
2021 |
Bcl-2-Protein Family as Modulators of IP<sub>3</sub> Receptors and Other Organellar Ca<sup>2+</sup> Channels. |
MCL1 |
| 22 |
31601689 |
10.3324/haematol.2019.220525 |
2021 |
Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. |
MCL1 |
| 23 |
32045477 |
10.1182/bloodadvances.2019000359 |
2021 |
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. |
MCL1 |
| 24 |
32126142 |
10.1182/bloodadvances.2019000844 |
2021 |
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. |
MCL1 |
| 25 |
32204955 |
10.1016/j.blre.2020.100672 |
2021 |
Targeting MCL-1 in hematologic malignancies: Rationale and progress. |
MCL1 |
| 26 |
32290241 |
10.3390/cancers12040938 |
2021 |
BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas. |
MCL1 |
| 27 |
32385800 |
10.1007/s12017-020-08600-8 |
2021 |
Downregulation of Microrna-421 Relieves Cerebral Ischemia/Reperfusion Injuries: Involvement of Anti-apoptotic and Antioxidant Activities. |
MCL1 |
| 28 |
32397113 |
10.3390/ijms21093323 |
2021 |
Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes. |
MCL1 |
| 29 |
32569380 |
10.1182/bloodadvances.2019001416 |
2021 |
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. |
MCL1 |
| 30 |
32600066 |
10.1080/13543784.2020.1789588 |
2021 |
Enhancing venetoclax activity in hematological malignancies. |
MCL1 |
| 31 |
32665700 |
10.1038/s41375-020-0968-9 |
2021 |
Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. |
MCL1 |
| 32 |
32731448 |
10.3390/biom10081114 |
2021 |
Predicted Hotspot Residues Involved in Allosteric Signal Transmission in Pro-Apoptotic Peptide-Mcl1 Complexes. |
MCL1 |
| 33 |
32764384 |
10.3390/cancers12082182 |
2021 |
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. |
MCL1 |
| 34 |
32860732 |
10.1002/psp4.12552 |
2021 |
Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl-1 Inhibitor AZD5991. |
MCL1 |
| 35 |
32862872 |
10.1016/S2152-2650(20)30464-X |
2021 |
Harnessing Apoptosis in AML. |
MCL1 |
| 36 |
32898245 |
10.1182/bloodadvances.2019001393 |
2021 |
AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. |
MCL1 |
| 37 |
32907612 |
10.1186/s12943-020-01254-x |
2021 |
Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. |
MCL1 |
| 38 |
32943617 |
10.1038/s41419-020-02944-6 |
2021 |
BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. |
MCL1 |
| 39 |
33039369 |
10.1016/j.humpath.2020.09.016 |
2021 |
Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. |
MCL1 |
| 40 |
33067607 |
10.1182/blood.2020008017 |
2021 |
Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition. |
MCL1 |
| 41 |
33125144 |
10.3892/or.2020.7797 |
2021 |
Dracocephalum palmatum Stephan extract induces caspase‑ and mitochondria‑dependent apoptosis via Myc inhibition in diffuse large B cell lymphoma. |
MCL1 |
| 42 |
33205684 |
10.1080/17474086.2020.1852923 |
2021 |
Apoptosis targeted therapies in acute myeloid leukemia: an update. |
MCL1 |
| 43 |
33259592 |
10.1182/blood.2020008528 |
2021 |
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. |
MCL1 |
| 44 |
33298918 |
10.1038/s41467-020-20136-w |
2021 |
Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors. |
MCL1 |
| 45 |
33446629 |
10.1038/s41408-020-00402-2 |
2021 |
MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas. |
MCL1 |
| 46 |
33471866 |
10.1371/journal.ppat.1009179 |
2021 |
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7. |
MCL1 |
| 47 |
33512431 |
10.1182/blood.2020007452 |
2021 |
Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. |
MCL1 |
| 48 |
33560385 |
10.1182/bloodadvances.2020003429 |
2021 |
Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. |
MCL1 |
| 49 |
33658484 |
10.1038/s41419-020-03351-7 |
2021 |
Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells. |
MCL1 |
| 50 |
33670870 |
10.3390/cancers13051002 |
2021 |
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. |
MCL1 |
| 51 |
33735476 |
10.1002/ajh.26163 |
2021 |
R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results. |
MCL1 |
| 52 |
33777762 |
10.3389/fonc.2021.618908 |
2021 |
CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With <i>MYC</i> and <i>BCL2</i> Rearrangements. |
MCL1 |
| 53 |
33803505 |
10.3390/biology10030234 |
2021 |
E3 Ubiquitin Ligase ASB17 Promotes Apoptosis by Ubiquitylating and Degrading BCLW and MCL1. |
MCL1 |
| 54 |
34007050 |
10.1038/s41375-021-01291-5 |
2021 |
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. |
MCL1 |
| 55 |
34061027 |
10.7554/eLife.67336 |
2021 |
Contingency and chance erase necessity in the experimental evolution of ancestral proteins. |
MCL1 |
| 56 |
34088885 |
10.18632/aging.203098 |
2021 |
Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology. |
MCL1 |
| 57 |
34339789 |
10.1016/j.ijbiomac.2021.07.166 |
2021 |
Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy. |
MCL1 |
| 58 |
34465776 |
10.1038/s41467-021-25405-w |
2021 |
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. |
MCL1 |
| 59 |
34475520 |
10.1038/s42003-021-02564-6 |
2021 |
The multiple mechanisms of MCL1 in the regulation of cell fate. |
MCL1 |
| 60 |
34576319 |
10.3390/ijms221810157 |
2021 |
BH3 Mimetics in Hematologic Malignancies. |
MCL1 |
| 61 |
34580292 |
10.1038/s41467-021-25963-z |
2021 |
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets. |
MCL1 |
| 62 |
30224339 |
10.1158/1078-0432.CCR-18-0867 |
2020 |
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. |
MCL1 |
| 63 |
30281155 |
10.1002/eji.201847585 |
2020 |
MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity. |
MCL1 |
| 64 |
30523053 |
10.3324/haematol.2018.204958 |
2020 |
Targeting BCL2 with venetoclax is a promising therapeutic strategy for double-proteinexpression lymphoma with <i>MYC</i> and <i>BCL2</i> rearrangements. |
MCL1 |
| 65 |
30538285 |
10.1038/s41418-018-0244-y |
2020 |
By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737. |
MCL1 |
| 66 |
30601084 |
10.1080/15384101.2018.1559557 |
2020 |
Mitotic slippage: an old tale with a new twist. |
MCL1 |
| 67 |
30626241 |
10.1080/10428194.2018.1563694 |
2020 |
MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. |
MCL1 |
| 68 |
30792387 |
10.1038/s41419-019-1407-6 |
2020 |
BCL-2 family isoforms in apoptosis and cancer. |
MCL1 |
| 69 |
30872780 |
10.1038/s41375-019-0442-8 |
2020 |
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. |
MCL1 |
| 70 |
31004002 |
10.1158/1078-0432.CCR-18-3275 |
2020 |
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal <i>In Vivo</i> in Relapsed Mantle Cell Lymphoma. |
MCL1 |
| 71 |
31117518 |
10.1021/acs.jmedchem.9b00455 |
2020 |
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1). |
MCL1 |
| 72 |
31161836 |
10.1080/10428194.2019.1622098 |
2020 |
Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. |
MCL1 |
| 73 |
31171817 |
10.1038/s41375-019-0503-z |
2020 |
Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. |
MCL1 |
| 74 |
31243099 |
10.1158/1535-7163.MCT-18-1023 |
2020 |
Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma. |
MCL1 |
| 75 |
31349760 |
10.1080/15384101.2019.1646068 |
2020 |
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors. |
MCL1 |
| 76 |
31387206 |
10.3390/cells8080829 |
2020 |
Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-x<sub>L</sub>. |
MCL1 |
| 77 |
31467227 |
10.21873/cgp.20138 |
2020 |
Association of Leukemia Target Genes <i>Tet2, Bcl2</i>, and <i>Slc23a2</i> in Vitamin C Pathways. |
MCL1 |
| 78 |
31533276 |
10.3390/genes10090718 |
2020 |
Allele-Specific Expression of CD4<sup>+</sup> T Cells in Response to Marek's Disease Virus Infection. |
MCL1 |
| 79 |
31543463 |
10.1016/j.ccell.2019.08.005 |
2020 |
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. |
MCL1 |
| 80 |
31692474 |
10.1107/S2059798319014116 |
2020 |
Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1. |
MCL1 |
| 81 |
31740676 |
10.1038/s41408-019-0249-x |
2020 |
Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. |
MCL1 |
| 82 |
31772331 |
10.1038/s41388-019-1122-x |
2020 |
Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. |
MCL1 |
| 83 |
31794606 |
10.1182/blood.2019001866 |
2020 |
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. |
MCL1 |
| 84 |
31801186 |
10.3390/ijms20236036 |
2020 |
Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma. |
MCL1 |
| 85 |
31894587 |
10.1002/lary.28441 |
2020 |
Apoptosis signaling molecules as treatment targets in head and neck squamous cell carcinoma. |
MCL1 |
| 86 |
31971799 |
10.1021/acs.jmedchem.9b01442 |
2020 |
Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins. |
MCL1 |
| 87 |
32014946 |
10.21873/anticanres.14035 |
2020 |
Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer. |
MCL1 |
| 88 |
32245312 |
10.18502/ijaai.v18i6.2181 |
2020 |
Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines. |
MCL1 |
| 89 |
32645016 |
10.1371/journal.pone.0234103 |
2020 |
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. |
MCL1 |
| 90 |
33198338 |
10.3390/cancers12113353 |
2020 |
BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic. |
MCL1 |
| 91 |
33292251 |
10.1186/s12935-020-01614-z |
2020 |
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. |
MCL1 |
| 92 |
27480872 |
10.1158/1078-0432.CCR-16-1315 |
2019 |
Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. |
MCL1 |
| 93 |
28485156 |
10.4149/neo_2017_404 |
2019 |
The Effects of Lentivirus-mediated shRNA Interference Targeting Mcl-1 on Growth of NK/T-cell Lymphoma. |
MCL1 |
| 94 |
28751770 |
10.1038/leu.2017.243 |
2019 |
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. |
MCL1 |
| 95 |
29241222 |
10.1038/bjc.2017.432 |
2019 |
Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. |
MCL1 |
| 96 |
29269870 |
10.1038/s41598-017-18368-w |
2019 |
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. |
MCL1 |
| 97 |
29348517 |
10.1038/s41419-017-0184-3 |
2019 |
NDRG2 contributes to cisplatin sensitivity through modulation of BAK-to-Mcl-1 ratio. |
MCL1 |
| 98 |
29352235 |
10.1038/s41419-017-0039-y |
2019 |
Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells. |
MCL1 |
| 99 |
29521234 |
10.2174/1568009618666180308105048 |
2019 |
Noxa: Role in Cancer Pathogenesis and Treatment. |
MCL1 |
| 100 |
29570100 |
10.1097/CAD.0000000000000616 |
2019 |
Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma. |
MCL1 |
Datasets
Models
